The continuing contribution of biodiversity to drug discovery

Current Opinion in Drug Discovery and Development

Volumn 1, Issue 1, 1998, Pages 71-76

  Harvey, Alan L ^a   Waterman, Peter G ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001781448     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rotheim P: Plant-Derived Drugs: Products, Technologiesand Application. Business Communications Co, Norwalk, Connecticut (1998).
2. Macilwain C: When rhetoric hits reality in debate on bioprospecting. Nature (1998) 392:535-540. Recent summary of the political implications of using biodiversity.
3. de Vries DJ, Hall MR: Marine biodiversity as a source of chemical diversity. DrugDev/7as(1994) 33:161-173.
4. Wall ME, Wani MC: Camptothecln and taxol: From discovery to clinic. JEthnopharmaco/ogy(199G) 51:239-254.
5. Pearce C: Biologically active fungal metabolites. Advances in Applied Microbiology(1997) 44:1-80.
6. Naik RQ, Kattige SI, Bhat SV, Alrejy B, de Souza NJ, Rupp RH: An antiinflammatory piperidinylbenzopyranone from Dysoxylum binectariterurrr. isolation, structure and total synthesis. Tetrahedron (1988) 44:2081-2086.
7. Harmon A, Weiss U, Silverton JA: Structure of rohitukine, the main alkaloid of Amoora rohituka (syn Aphanamixis polystachyâ) (Meliaceae). Tetrahedron Letters (1979) 721-724.
8. Sedlacek HH, Czech J, Naik R, Kaur G, Worland P, Losiewicz M: Flavopiridol L86-8275, NSC-S49890), a new kinase inhibitor for tumor-therapy. Inter J Oncology (1996) 9:1143-1168. A comprehensive review of the preclinical pharmacology of llavopiridol and a review of the role ofcyclins.
9. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G(1) arrest with inhibition of cyclindependent kinase (CDK)2 and CDK4 in human breastcarcinoma cells. Cancer Research (1996) 56:2973-2978. Results demonstrate the actions of flavopiridol on cdk enzymes.
10. Deazevedo WF, Mueller-Dieckmann HJ, Sehulzegahmen U, Worland PJ: Structural basis for specificity and potency of a flavonold inhibitor of human CDK2, a cell-cycle kinase. Proc NatAcadSci USA (1996) 93:2735-2740.
11. Drees M, Dengler WA, Roih T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA, Fiebig HH: Flavopiridol (L868275): sélective antitumor activity In vitro. Clinical Cancer Research (1997) 3:273-279. Results demonstrate flavoplridol's selective actions on particular tumor cells.
12. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM: Early Induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood (1998) 91:458-465.
13. Konig A, Schwarte GK, Mohammad RM, AI Katib A, Gabrilove JL: The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood (1997) 11:307-4312.
14. Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D: Potentiation of apoptosis by flavopiridol in mitomycin C-treated gastric and breast cancer cells. Clinical Cancer Research (1997) 3:1467-1472.
15. Bible KC, Kaufmann SH: Flavopiridol - a cytotoxic flavone that induces cell-death in noncycling A549 human lungcarcinoma cells. Cancer Research (1996) 56:4856-4861. Results indicate that flavopiridol can be cytotoxic as well as cytostatlc.
16. Robinson CS, Slee AM, Kerr JS: Flavopiridol inhibits angiogenesis. FASEB J (1997) 11:369.
17. Bible KC, Kaufmann SH: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration. Cancer Research (1997) 57:3375-3380.
18. Medina JH, Pena C, Levi de Stein M, Wolfman C, Paladini AC: Benzodiazepine-like molecules as well as other ligands for the brain benzodiazepine receptor are relatively common constituents of plants. Biochem Biophys Res Comm (1989) 165:547-553.
19. Medina JH, Viola H, Wolfman C, Marder M, Wasowski C, Calvo D, Paladini AC: Flavonoids: a new family of benzodiazepine receptor ligands. Neurochem Res (1997) 22:419-425. A short review of a new class of agents with a selective effect on benzodiazepine receptors in vivo and in vitro.
20. Medina JH, Paladini AC, Wolfman C, Levi de Stein M, Calvo D, Diaz L: Chrysin (5,7-dihydroxyflavone), a naturally-occuring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol (1990) 40:2227-2231.
21. Marder M, Viola H, Wasowski C, Wolfman C, Waterman PG, Medina JH, Paladini AC: Cirsiliol and caffeic acid ethyl ester, isolated from Salvia guaranitica, are competitive ligands for the central benzodiazepine receptors. Phytomedicine(1996) 3:29-31.
22. Chicarelli-Robinson Ml, Gibbons S, McNicholas C, Robinson N, Moore M, Faulh U, Wrigley SK: Plants and microbes as complementary sources of chemical diversity for drug discovery. In: Phytochemical Diversity. A Source of New Industrial Products, Wrigley S, Hayes M, Thomas R, Chrystal E (Eds), Royal Society of Chemistry, Cambridge, (1997):30-40. A brief review of the experience of Xenova on screening natural products from different sources.
23. Marder M, Viola H, Wasowski C, Wolfman C, Waterman PG, Medina JH, Paladini AC: 6,3′-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties. Bioorg Med Chem Letters (1995) 5:2717-2720. Results indicate very high activity in vivo, with few sedative or muscle relaxant effects.
24. Marder M, Viola H, Wasowski C, Wolfman C, Waterman PG, Cassels BK, Medina JH, Paladini AC: 6-Bromoflavone, a high affinity ligand for the central benzidiazepine receptor is a member of a family of active flavonoids. Biochem Biophys Res Comm (1996) 223:384-389.
25. Ainsworth AM, Chicarelli-Robinson Ml, Copp BR, Fauth U, Hylands PJ, Holloway JA, Latif M, Obeirne GB, Porter N, Renno DV, Richards M, Robinson N: Xenovulene-A, a novel GABA-benzodiazepine receptor binding compound produced by Acremonium strictum. J Antibiotics (1995) 48:568-573.
26. Raggatt ME, Simpson TJ, Chicarelli-Robinson Ml: Biosynthesis of xenovulene-A: formation of a cyclopentanone via a unique ring expansion-ring contraction mechanism. Chem Commun (1997) 22:2245-2246.
27. Blackburn M, Fauth U, Katzer W, Renno DV, Trew S: Optimization of fermentation conditions for the production of a novel GABA-benzodiazepine receptor agonist by Acremonium strictum. JIndustMicrobiol'(1997) 17:36-40.
28. A-benzodiazepine receptor.
29. Kashman Y, Gustafson KR, Fuller RW, Cardellina JH, McMahon JB, Currens MJ, Buckheit RW, Hughes SH, Cragg GM, Boyd MR: HIV inhibitory natural products. 7. The calanolides, a novel HIV-lnhibitory class of coumarin derivatives from the tropical rain-forest tree, Calophyllum lanigerum. J Med Chem (1992) 35:2736-2743.
30. Kashman Y, Gustafson KR, Fuller RW, Cardellina JH, McMahon JB, Currens MJ, Buckheit RW, Hughes SH, Cragg GM, Boyd MR: Correction: The calanolides, a novel HIV-lnhibitory class of coumarin derivatives from the tropical rain-forest tree, Calophyllum lanigerum. J Med Chem (1993)36:1110
31. Patil AD, Freyer AJ, Eggleston DS, Haltiwanger RC, Bean MF, Taylor PB, Caranfa MJ, Breen AL, Bartus HR, Johnson RK, Hertzberg RP, Westley JW: The inophyllums, novel inhibitors of HIV-1 reverse transcriptase from the Malaysian tree Calophyllum Inophyllum. J Med Chem (1993)36:4131-4138.
32. McKee TC, Cardellina JH, Dreyer GB, Boyd MR: The pseudocalanolides: structure revision of calanolides C and D. J Nat Prod (1995) 58:916-920.
33. Cragg GM, Boyd MR, Christini MA, Kneller R, Mays TD, Mazan KD, Newmann DJ, Sausville EA: Screening of natural products of plant, microbial and marine origin. In: Phytochemlcal Diversity. A Source of New Industrial Products. Wrigley S, Hayes M, Thomas R, Chrystal E (Eds), Royal Society of Chemistry, Cambridge, (1997):1-29.
34. Taylor PB, Gulp JS, Debouck C, Johnson RK, Palil AD, Woolf DJ: Kinetic and mutational analysis of human-immunodeficiency-virus type-1 reverse transcriptase by inophyllums, a novel class of non-nucleoside inhibitors. J Biol Chem (1994) 269:6325-6331. An investigation of the nature of the inhibition of reverse transcriptase and its specificity.
35. Hoechst AG (Naik RG, Lal B, Rupp RH, Sedlacek HH, Dickneite G, Czech J): New 4H-1-benzopyran-4-one derivatives and pharmaceutical use. EP-00366061-A (1990).